InMode (INMD) vs LivaNova (LIVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
LivaNova (LIVN) has outperformed InMode (INMD) over the past year, gaining 46.6% versus a loss of 10.6%. Over five years, LIVN leads with a -8.9% price change compared with -83.0% for INMD. LivaNova is the larger company by market cap ($4.20 billion vs $817.7 million), about 5.1 times the size.
On valuation, InMode trades at a lower forward P/E (10.4x vs 16.3x for LivaNova).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMD | LIVN |
|---|---|---|
| Share price | $14.21 | $76.39 |
| Market cap | $817.70M | $4.20B |
| 1-day change | +0.92% | +0.63% |
| YTD return | -3.27% | +24.15% |
| 1-year return | -10.57% | +46.59% |
| 5-year return | -82.96% | -8.94% |
| P/E ratio (TTM) | 11.74 | 22.60 |
| Forward P/E | 10.36 | 16.31 |
| EPS (TTM) | $1.21 | $3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.39B |
| Revenue growth (YoY) | — | +10.74% |
| Net income (latest FY) | — | $-242.47M |
| Gross margin | — | 67.71% |
| Operating margin | — | 14.36% |
| Net margin | — | -17.47% |
| 52-week high | $16.67 | $85.76 |
| 52-week low | $12.72 | $48.82 |
| Distance from 52-week high | -14.76% | -10.93% |
| Analyst consensus | none | buy |
| Avg. price target upside | +13.79% | +18.54% |
| Average volume | 501.37K | 648.38K |
| Shares outstanding | 57.54M | 54.93M |
| Employees | 660 | 3,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LivaNova is about 5.1 times larger than InMode by market value ($4.20B vs $817.70M).
- LIVN has outperformed INMD by 57.2 percentage points over the past year.
- LivaNova trades at a higher earnings multiple (22.6x vs 11.7x trailing P/E).
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
About LivaNova
LIVN stock →LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,300 employees
INMD vs LIVN FAQ
Which is bigger, InMode or LivaNova?
LivaNova (LIVN) is larger, with a market capitalization of $4.20B compared with $817.70M for InMode (INMD).
Which stock has performed better over the past year, INMD or LIVN?
LIVN returned +46.59% over the past 12 months, compared with -10.57% for INMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, INMD or LIVN?
INMD has the lower trailing P/E at 11.7, versus 22.6 for LIVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are InMode and LivaNova in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.